Searchable abstracts of presentations at key conferences in endocrinology

ea0044p169 | Neuroendocrinology and pituitary | SFEBES2016

Significance of cumulative GH exposure in patients with acromegaly: comparison between patients in whom control was achieved and patients with active disease

Varadhan Lakshminarayanan , Clayton Richard

Aim: The aim of the study was to assess the differences between patients in remission in acromegaly and those with active ongoing disease, using cumulative GH measurement as risk factor for various complications.Methods: A retrospective observational analysis of all patients with acromegaly treated at a tertiary referral centre since the initiation of service (~50 years) was conducted. Cumulative GH exposure was calculated as a sum of averages of GH leve...

ea0059p131 | Neuroendocrinology and pituitary | SFEBES2018

The importance of achieving disease control in Acromegaly: a retrospective single centre analysis

Varadhan Lakshminarayanan , Jose Biju , Clayton Richard

Aim: Acromegaly is associated with higher mortality and morbidity, and achieving disease control can be challenging. The aim of this study was to assess the morbidity and mortality associated with active acromegaly compared to patients in whom disease control was achieved.Methods: Retrospective analysis of all patients treated with acromegaly at a university hospital between 1948 and 2014 was performed. Mortality rates and development of new cardiovascul...

ea0090p156 | Pituitary and Neuroendocrinology | ECE2023

Incidence of complications of acromegaly 10 years after achieving biochemical control of GH – a single centre retrospective observational study

Mulholland Sarah , Clayton Richard , Jose Biju , Varadhan Lakshminarayanan

Aim: Acromegaly is associated with multiple co-morbidities including diabetes mellitus (DM), obstructive sleep apnoea (OSA), arthropathy, cardiovascular events and malignancies. Early diagnosis and treatment, with an intention to cure or control the growth hormone (GH) exposure can reduce risk of these complications. The aim of this study is to assess the development of acromegaly-related complications amongst patients who have completed at least 10 years of follow up after ac...

ea0034p144 | Clinical practice/governance and case reports | SFEBES2014

Madness on the medical ward: ectopic ACTH producing tumour

Puttanna Amar , Patel Viraj , Raskauskiene Diana , Clayton Richard

A 51-year-old Afro-Caribbean lady with a history of primary hyperparathyroidism, type 2 diabetes and hypertension was admitted with confusion. Her medication at the time included five anti-hypertensives.She was treated for an infection but despite a long course of antibiotics she remained confused with visual hallucinations and aggression.She was noted to have resistant hypertension with systolic blood pressures over 220 mmHg and p...

ea0028p202 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2012

Bariatric surgery and Vitamin D deficiency: Pre-operative treatment or post-operative supplementation

Ataullah Zahid , Cheruvu Chandra , Clayton Richard , Varughese George , Varadhan Lakshminarayanan

Introduction: Bariatric surgery is an important treatment option for morbid obesity. The current guidelines recommend testing and supplementation of vitamin D postoperatively. The aim of our study was to assess the need for preoperative proactive supplementation of vitamin D. Methods All patients who had restrictive bariatric surgery (laparoscopic gastric bypass or sleeve gastrectomy) between January 2010 and June 2011 were included. Data was collected retrospectively from com...

ea0025p56 | Clinical biochemistry | SFEBES2011

Hormone profile of patients referred for Bariatric surgery

Varadhan Lakshminarayanan , Cheruvu C V N , Varughese George , Clayton Richard

Aim: An increasing proportion of patients are referred to endocrine clinics for assessment of an endocrine reason for obesity. The aim of our study was to assess the hormone profiles of patients referred for bariatric surgery.Methods: Patients referred to bariatric surgery clinic were investigated for hypothyroidism (TSH, T4), Cushing’s disease (2 mg-overnight dexamethasone suppression test), acromegaly (IGF1) and Vitamin D deficiency (PT...

ea0025p223 | Pituitary | SFEBES2011

Mortality in cushing’s disease: stoke-on-trent data and meta-analysis

Clayton Richard , Raskauskiene Diana , Reulen Raoul , Jones Peter

There are very limited data on long-term mortality in pituitary ACTH dependent Cushing’s disease (CD).We report on our data from Stoke-on-Trent, UK, spanning 50 years and provide a meta-analysis of six other reports which addressed mortality of CD. Case records of 60 CD patients from 1958-31 Dec 2009 from Stoke-on-Trent were reviewed. The standardised mortality ratio (SMR) overall and separately for patients in remission and having persistent diseas...

ea0021p244 | Pituitary | SFEBES2009

Management of non-functioning pituitary adenomas in a University Hospital: aretrospective analytical audit

Varadhan Lakshminarayanan , Mukherjee Arjun , Brown Maureen , Clayton Richard , Hanna Fahmy

Introduction: Pituitary tumors account for 15% of all intracranial neoplasms and could remain asymptomatic for a significant period. We conducted a retrospective analysis to assess pattern of referrals and management of non-functioning pituitary adenomas at our tertiary referral centre.Methods: Data was collected on referrals for NFA received at our university hospital from 2005 to 2008. Medical records, radiology reports and endocrine department data we...

ea0013p293 | Thyroid | SFEBES2007

Persistent hypothyroidism despite optimal therapy: time to rethink

Varughese George , Tahrani Abd , Khan Tahir , Davis Julie , Clayton Richard , Hanna Fahmy

We report a 47-year old lady who was initially diagnosed to have primary hypothyroidism nearly four years ago; on treatment with levothyroxine sodium (LT4) 150 μcg daily. Despite reasonable doses of LT4, and being fully compliant with her therapy, at no stage her TSH was less than 20 mU/L (Table-1). Malabsorption was ruled out and there were no clinical features to suggest this. When she was reviewed...

ea0015p258 | Pituitary | SFEBES2008

Monitoring acromegaly disease activity with growth hormone and insulin like growth factor-I in 501 patients

Sherlock Mark , Alonso Aurora Aragon , Ayuk John , Clayton Richard N , Sheppard Michael C , Bates Andy , Stewart Paul

The aim of treatment in patients with acromegaly is to achieve serum GH/ IGF-I concentrations associated with cure or normalisation of mortality. Using the West Midlands acromegaly database (n=501) we assessed a number of parameters in the follow up of patients with acromegaly including the reliability of basal fasting GH in predicting nadir or mean GH during oral glucose tolerance test (OGTT) or growth hormone day curve (GHDC) respectively, the degree of discordance be...